Search
Research
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk indigenous infants (PREV-IX-COMBO)Otitis media (OM) starts within weeks of birth in almost all Indigenous infants living in remote areas of the Northern Territory (NT).
Research
Evolution, Evidence and Effect of Secondary Prophylaxis Against Rheumatic FeverThe association between group A streptococcal infection and rheumatic fever (RF) was established in the early 20th century.
Research
Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelinesSystematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations
Research
The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyodermaWe conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
Research
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Rheumatic heart disease across the Western Pacific: not just a Pacific Island problemWe aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden
Research
Clinical development strategy for a candidate group A streptococcal vaccineThis review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin
Research
Long-term outcomes from acute rheumatic fever and rheumatic heart disease: A Data-Linkage and Survival Analysis ApproachAdverse outcomes for people with acute rheumatic fever and rheumatic heart disease and the effect of comorbidities and demographic factors on these outcomes
Research
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart DiseaseRheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.
Research
Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infectionsThis paper reports on treatment, and preventing infection in close contact, of invasive group A streptococcal (iGAS) using the antibiotic clindamycin and...